A Study to Evaluate the Outcomes of Cannabinoid (CBD) Roll-on Topical Stick in Primary Total Knee Arthroplasty
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04585230 |
Recruitment Status :
Enrolling by invitation
First Posted : October 14, 2020
Last Update Posted : October 19, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Total knee arthroplasty (TKA) is one the most common surgical treatments performed for end stage degenerative arthritis of the knee. More than 700,000 procedures are currently performed yearly in the United States. This procedure usually results in moderate-to-severe pain in the immediate post-operative period. Optimal pain control may allow early mobilization, accelerate rehabilitation, improve patient satisfaction, decrease length-of-stay, and optimize functional outcomes. The challenge, however, is to manage pain with alternative methods, reducing the role of opiate medications, which are highly addictive with myriad side effects.
In this prospective randomized double-blinded controlled study, the investigators aim to evaluate the benefits of an over-the-counter (OTC) transdermal CBD preparation in patients undergoing primary total knee arthroplasty as a novel adjunct to the standard multi-modal analgesic regimen, to reduce postoperative pain and reduce the need for opiates after total knee arthroplasty.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Pain, Joint Pain, Postoperative Total Knee Arthroplasty | Drug: CBD Drug: Mineral Oil Drug: Placebo | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 92 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Care Provider) |
Primary Purpose: | Treatment |
Official Title: | Prospective Blinded Randomized Controlled Trial Evaluating the Outcomes of Cannabinoid (CBD) Roll-on Topical Stick in Primary Total Knee Arthroplasty |
Estimated Study Start Date : | October 12, 2020 |
Estimated Primary Completion Date : | May 28, 2021 |
Estimated Study Completion Date : | May 28, 2021 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Group 1: (CBD + MO cohort)
Roll on stick containing CBD and mineral oils (CBD + MO cohort)
|
Drug: CBD
CBD oil Roll-On Stick Drug: Mineral Oil Mineral Oil- Roll on Stick |
Active Comparator: Group 2: (MO cohort)
Roll on stick containing mineral oils only (MO cohort)
|
Drug: Mineral Oil
Mineral Oil- Roll on Stick |
Active Comparator: Group 3: (CBD Cohort)
Roll on stick containing CBD only (CBD cohort)
|
Drug: CBD
CBD oil Roll-On Stick |
Placebo Comparator: Group 4: (Roll-on stick only with NO CBD or MO-placebo cohort)
Roll on stick with neither CBD nor essential oils (Roll-on stick only with NO CBD or MO-placebo cohort)
|
Drug: Placebo
Roll- On stick with no CBD and no Mineral Oil |
- Postoperative change in pain and change the need for opiates after total knee arthroplasty. [ Time Frame: 14 days ]opioid consumption after surgery will be calculated in morphine equivalents

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 80 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Patients who have general anesthesia
- Patients who have documented allergic reactions to ropivacaine in the local infiltration agents
- Patients who have a contra-indication to the use of non-steroidal anti-inflammatory medications or are using therapeutic anticoagulation precluding them from using non-steroidal anti-inflammatory medications
- Patients unable to complete a 100-ft walk baseline
- Patients undergoing total knee arthroplasty as a conversion procedure following previous surgery
- Patients undergoing TKA for posttraumatic arthritis
- Patients undergoing TKA for steroid-induced or spontaneous avascular necrosis
- Workers compensation patients
- Patients refusing or not candidates for peripheral nerve blocks
- Patients undergoing unicompartmental knee arthroplasty
- Patients undergoing patellofemoral arthroplasty
- Patients undergoing bilateral simultaneous or sequential primary total knee arthroplasty within the same hospital stay
- Patients who have previously reported allergy to tetrahydrocannabinol or other cannabinoid compounds or develop allergic reactions to the formulation following use
- Patients who are pregnant or choosing to be pregnant during the 6-week study period or are breast feeding during the study period
- Patients who are on chronic narcotics pre-operatively
- Patients who have end-stage cirrhosis, end-stage renal failures, or psychiatric conditions preventing adequate assessment of study outcome metrics
- Patients with adequate cognitive function to participate and complete questionnaires for the study.
- Patients unable or unwilling to follow-up and complete questionnaires for the study
- Patients with active cancer and undergoing treatment precluding the assessment of outcome metrics
- Patients with a history or diagnosis of chronic pain syndrome or Complex regional pain syndrome (CRPS)
- Patients who are determined to be in severe pain from other concomitant conditions
Exclusion Criteria:
- patients <18 and >80
- any patient who does not meet the inclusion criteria listed for this study

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04585230
United States, Pennsylvania | |
Rothman Orthopaedic Institute | |
Philadelphia, Pennsylvania, United States, 19107 |
Responsible Party: | Rothman Institute Orthopaedics |
ClinicalTrials.gov Identifier: | NCT04585230 |
Other Study ID Numbers: |
JLON20P.202 |
First Posted: | October 14, 2020 Key Record Dates |
Last Update Posted: | October 19, 2020 |
Last Verified: | October 2020 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | No |
Arthralgia Pain, Postoperative Postoperative Complications Pathologic Processes Pain Neurologic Manifestations |
Joint Diseases Musculoskeletal Diseases Mineral Oil Emollients Dermatologic Agents |